Evidera | PPD | COREVITAS
Part of Thermo Fisher Scientific

Real-world Evidence for Real-life Insights

Our industry-leading real-world evidence (RWE), health economics and outcomes research (HEOR), and market access solutions, backed by a multi-disciplinary team of scientific experts, provide integrated strategic consulting, scientific expertise, and global operational capabilities across the product development and commercialization life cycle.

Proven Solutions throughout the Product Life Cycle

Our customized, integrated solutions are shaped by our deep understanding of challenging client needs

Pre-Clinical > Phase I > Phase II > Phase III > Filing/Pre-Launch > Post-Launch

- Inform/optimize clinical trial design & implementation
- Develop/refine regulatory, patient-centered research & market access strategy with evidence roadmap
- Generate patient & HEOR evidence to support future HTA submissions
- Generate RWE for safety & comparative effectiveness to demonstrate value
- Optimize market access & reimbursement
- Optimize uptake

Market Access Regulation Changes

The EU Health Technology Assessment (HTA) Regulation and the Inflation Reduction Act (IRA) brought about major changes in the EU and US access landscape that require early and strategic preparation to ensure an optimal evidence package to demonstrate value. Generation of RWE can be a useful tool in addressing the challenges arising from these new access policies and preparing for stakeholder discussions.

Our strategic consultants have been focusing on navigating the changes brought about by HTA Regulation and the IRA on supporting clients to plan and prepare for the new landscape in the EU and the US, thanks to our unique combination of strategy consulting and technical expertise.

Speak with our experts


Martin Parkinson
martin.parkinson@evidera.com


Caroline Delaitre-Bonnin
caroline.delaitre-bonnin@evidera.com


Malinda O'Donnell
malinda.odonnell@evidera.com

Complex Reimbursement Hurdles

Reimbursement hurdles in HTA countries are higher and more complex than ever before. Our clients value our expertise in HEOR strategy and developing fit-for-purpose tools for successful submissions. These tools include robust evidence synthesis and indirect treatment comparisons, as well as advanced statistical analyses of trial data—all presented within the value-focused narrative of the submission dossier.

Our global team of consultants brings their extensive experience in economic modeling, HTA-compliant literature reviews, complex statistical analyses, and market access communications to each of our client partnerships, ensuring each client has a strong HEOR strategy and is prepared for reimbursement discussions with a sound evidence package.

Speak with our experts


Malinda O'Donnell
malinda.odonnell@evidera.com


Agnes Benedict
agnes.benedict@evidera.com


Sohan Deshpande
sohan.deshpande@evidera.com


Irina Proskorovsky
irina.proskorovsky@evidera.com

Stop by booth 901 to speak with us about any of our solutions!

Evidera | PPD | COREVITAS

Part of Thermo Fisher Scientific

Patient Insights and Inclusion

Our clients are partnering with us to address **the latest questions in patient-centered research (PCR):**

- What does the FDA's fourth Patient-Focused Drug Development (PFDD) guidance mean for my outcome strategy?
- When is it optimal to conduct exit interviews?
- What does the FDA's benefit-risk assessment guidance mean for use of patient preference data?
- Does National Institute for Health and Care Excellence's (NICE) methods guide mean I should use vignette studies to estimate patient and caregiver health state utility?

We partner with our clients to design a PCR strategy that optimizes rapid patient insights, patient partnering, product strategy, and regulatory-quality patient-experience data to increase chances of market success for products.

Speak with our experts


Carla Dias Barbosa
carla.dias-barbosa@evidera.com


Louis Matza
louis.matza@evidera.com


Matt Quaife
matt.quaife@evidera.com


Don Bushnell
don.bushnell@evidera.com

Publications and Scientific Communications

With our **deep knowledge of HEOR** combined with our 360° approach to excellence, we are skilled at driving your HEOR publications to successful completion.

Engaging us for your HEOR publication needs offers the simplicity and advantage of keeping studies and their dissemination with a single expert provider.

Speak with our expert


Phil Leventhal
Phil.Leventhal@evidera.com

Real-world Data and Evidence Solutions

The increasing acceptance of real-world data (RWD) and RWE by regulators and payers has **increased their use across the life cycle** to demonstrate safety, effectiveness, and value and optimize market access and uptake. With the **proliferation in RWD** across the globe, our clients are often unsure which RWD are optimal to generate the RWE needed to meet their objectives.

Real-world Evidence

We guide our clients to the study design that best addresses their research needs by combining in-depth study design expertise and data expertise, operational excellence, and innovative tech and AI-enabled solutions. We maximize investment and reduce costs by designing and delivering studies and services that:

(1) Improve the likelihood and speed of regulatory approval;
(2) Optimize patient access and reimbursement;
(3) Enhance evidence for post-marketing requirements.

Real-world Data

We identify and select RWD to optimize client research needs. Proprietary data sources, experience with 100+ global data sources, advanced technologies, and expert data scientists provide the insights our clients need to inform decision-making.

- Proprietary data solutions providing **real-time market data in 40+ countries across 30+ indications** from 1.7M healthcare professionals panel
- CorEvitas regulatory-grade disease **registry data** on 100k patients in **Dermatology, Rheumatology** (US/Japan), **Gastrointestinal**, and **Neurology** immune-mediated diseases

Speak with our RWD and RWE experts


Delphine Saragoussi
delphine.saragoussi@evidera.com


Alice Rouleau
alice.rouleau@evidera.com


Heather Von Allmen
hvonallmen@corevitas.com


Dimitra Lambrelli
dimitra.lambrelli@evidera.com


Mireia Raluy
mireia.raluy@evidera.com

Scan the QR code for ISPOR EU 2024 resources

Stop by booth 901 to speak with us about any of our solutions!

Events

1. Patient Preferences Workshop & Networking Event. *Sun 17 Nov. 6:00–8:00PM. Location: AC Hotel Barcelona Fórum.*
2. Strategies for Success Workshop: Navigate the EU HTA Regulation. *Mon 18 Nov. 7:00–9:00PM. Location: AC Hotel Barcelona Fórum.*

Presentations

1. 149: Breakout Session—How Do We Unleash the Ambition of the EU HTA Regulation through Practical Methodological Solutions? (M Parkinson) *Mon 18 Nov. 5:00–6:00PM*
2. 243: HEOR Theatre—Better and Faster: Automating Model Building and Statistical Analyses (A Benedict, J Ishak, A Ambavane) *Tues 19 Nov. Exhibit Hall Theatre 3:45–4:15PM*
3. 227: Breakout Session—How Can We Move from Generating Robust Patient Preference Information to Producing Decision-Ready Outputs? (S Heidenreich) *Tues 19 Nov. 1:45–2:45PM*
4. 251: Breakout Session—Interplay between Budget Impact Analysis (BIA) and Cost-Effectiveness Analysis (CEA); Theory Vs Practice (J Caro) *Tues 19 Nov. 5:00–6:00PM*
5. 318: Breakout Session—Taking the "Greener" Pill—a Case Study for Incorporating Carbon Footprint in Health Technology Assessment (M Cohen, R Chapman, K Marczell) *Wed 20 Nov. 10:00–11:00AM*

Posters

Monday, 18 November:

1. Authoring of Peer-Reviewed Articles on the Experiences of Patients With Rare Diseases by Patients and Their Caregivers: A Rapid Review (P Leventhal, D Drachmann, R Schinner, S Skovlund) *Session 1*
2. Validation of a Questionnaire to Assess Emotional Impact of Treatment for Type 2 Diabetes (EIDTQ) (L Matza, K Cutts, K Malley, KS Coyne) *Session 1*
3. Patient Preferences of Health State Utilities Associated With Glycemic Variability in People Living With Type 1 and Type 2 Diabetes (L Matza, K Stewart) *Session 1*
4. A Systematic Literature Review of Economic Burden and Medication Adherence With Subcutaneous Versus Intravenous Oncology Therapies (C Casañas Comabella, P Sarocco) *Session 1*
5. Understanding Physicians Decision Making Processes When Treating Mild -to-Moderate Chronic Kidney Disease: A Qualitative Study (K Meginnis) *Session 1*
6. Does Baseline Disease Severity Impact the Meaningful Score Difference of Clinical Outcome Assessments? Results From Studies in Two Itching-Related Skin Conditions (D Rodriguez, C Dias-Barbosa, K Bailey, D Filipenko) *Session 1*
7. The Burden of Long COVID on Quality of Life and Daily Functioning (N Stapleton, H Burnett, J Knight) *Session 1*
8. Estimated Cost of Automated Red Cell Exchange Transfusion (ARCET) for Treatment of Sickle Cell Disease (SCD) in the English NHS: Data from a Longitudinal Real-World Cohort (C Rice, S Carvalho, J Davidson) *Session 1*
9. Polihexanide and Betaine (PSGX) Containing Solution Versus Saline for the Treatment of Leg Uclers: A Comparative Cost Analysis Study Using Real-World Data From England (C Rice, J Davidson) *Session 1*
10. Artificial Intelligence Tools for PICO Prediction: A New Reality or a Future Dream? (Himani Jaiswal, P Rolska-Wójcik, C Delaitre-Bonnin) *Session 2*
11. Patient Preferences and Health State Utilities Associated With Frequency of Basal Insulin Administration for Type 1 and Type 2 Diabetes (K Stewart, L Matza) *Session 2*
12. Incidence of Solar Retinopathy and Photokeratitis in Private Clinic Post 2017 and 2024 Solar Eclipses Across the USA (N Boucher) *Session 2*
13. Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses (P Kazmierska, G Bungey) *Session 2*
14. Real-world Healthcare Resource Utilization and Costs in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in China (L Ban) *Session 2*
15. Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-Small Cell Lung Cancer (NSCLC) (A Rai, V Ikoro, A Berger) *Session 2*
16. How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US) (A Berger) *Session 2*

Posters

Tuesday, 19 November:

1. A Framework for Re-Thinking Evidence Generation Requirements in the United States: It's Time to Meet Expectations of the Inflation Reduction Act (A D'Ausilio, R Arora, B Connelly, A Berger, H Jain) *Session 3*
2. Representativeness and Coverage of Death Data in the DeSC Healthcare Database in Japan (A Hamaguchi, A Pulfer, D Lambrelli) *Session 3*
3. Understanding the Patient Experience in Early Breast Cancer (eBC): A Review of Patient-Reported Outcomes Measures (PROMs) Used in Real-World Evidence (RWE) (A Duenas, C Clucas, K Kornalska, P Swinburn) *Session 3*
4. Leveraging the DeSC Healthcare Database for Alzheimer's Disease (AD) Research in an Aging Population in a Real-World Setting in Japan (A Hamaguchi, A Pulfer, D Lambrelli) *Session 4*
5. Development of a US-Based, Real-World, Ophthalmology Registry Based on Automated EHR Data Extraction to Support Opportunities for Clinical and Health Economics and Outcomes Research in Eyecare (N Boucher, A Berger) *Session 4*
6. Characteristics of Ovarian Cancer Patients: A Real-World Perspective for First-Line Maintenance Treatment Choice After 1st Line Platinum Based Induction Therapy Across EU4 & UK (K Palhares) *Session 4*
7. Deriving an Analytical Solution to Inversion of Royston/Parmar Restricted Cubic Spline Parametric Survival Models for Discrete Event Simulation (G Bungey, Jorgen Moller) *Session 4*
8. How to Manage the Multiple PICOs and Challenging Timelines in Systematic Reviews for JCA Submissions (S Deshpande) *Session 4*
9. Feasibility of GPT-4-Based Content Extraction to Identify Eligible Titles and Abstracts in a Systematic Literature Review (SLR) (L Mittal) *Session 4*
10. Automated Extraction of Cost-Effectiveness Models Data from Health Technology Assessment Submissions Using Large-Language Models (LLMS): Does the Prompting Approach Matter? (G Szabo, A Pinsent, M Slim, S Sullivan, A Benedict, S Rivolo) *Session 4*
11. Long COVID: A Costly Condition Imposing Substantial Burden on Society (J Knight, H Burnett, N Stapleton) *Session 4*
12. Gap Analysis of Patient-Reported Outcome Measures for Systemic Lupus Erythematosus (M Anatchkova, T Fikre) *Session 4*

Posters

Wednesday, 20 November:

1. Assessment of Health State Utilities Associated with Being a Caregiver for a Person With Alzheimer's Disease With Mild Cognitive Impairment or Dementia (L Matza, Timothy Howell) *Session 5*
2. Unlocking the Potential of Interoperable Linked Low-Latency National Health Data in England to Protect Vulnerable Patients While Safeguarding their Privacy: A Brave New World (N Justo, Y Lu, K Evans, V Olson, D Turner) *Session 5*
3. Automated Data Extraction in Systematic Literature Reviews (SLRs): Assessing the Accuracy and Reliability of a Large Language Model (LLM) (C Casañas Comabella) *Session 5*
4. Improper Age-Adjustment of Health State Utilities in Cost-Effectiveness Models: Assessing the Impact and Key Drivers (W Morris, G Bungey) *Session 5*
5. Searching Clinical Trial Registries in Systematic Literature Reviews (SLR): Which and Why? (L Mittal) *Session 5*
6. Estimated Incremental Direct All-Cause Healthcare Costs Associated with Multimorbidity Amongst Patients with Sickle Cell Disease (SCD) in England (C Rice, S Carvalho, J Davidson) *Session 5*
7. Understanding the Experiences of People Living With Chronic Pruritus of Unknown Origin: Development of a Disease Conceptual Model (C Dias-Barbosa, K Bailey) *Session 5*
8. Development of a Conceptual Disease Model of the Patient Experience of Systemic Lupus Erythematosus (M Anatchkova, T Fikre) *Session 5*

Scan the QR code for ISPOR EU 2024 resources